Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis
Amlitelimab treatment significantly reduced clinical and biomarker responses, and was well tolerated in adults with AD through week 52. Sustained responses were observed in the majority of patients for 28 weeks after they had stopped taking amlitelimab.
Authors
- Peter Foley (ORCID: https://orcid.org/0000-0001-5891-5607)
- Kim Papp (ORCID: https://orcid.org/0000-0001-9557-3642)
- Anne-Catherine Solente
- Fabrice Hurbin (ORCID: https://orcid.org/0000-0002-2230-7180)
- Charles W Lynde (ORCID: https://orcid.org/0000-0001-9163-5463)
- John T. O’Malley (ORCID: https://orcid.org/0000-0002-9968-1517)
- Sonya Davey (ORCID: https://orcid.org/0000-0003-4907-9920)
- Karl Yen (ORCID: https://orcid.org/0009-0002-2337-2045)
- Xiaodan Wei (ORCID: https://orcid.org/0000-0002-9160-6360)
- Margitta Worm (ORCID: https://orcid.org/0000-0002-3449-1245)
- Samuel Adelman
- Charlotte Bernigaud (ORCID: https://orcid.org/0000-0002-4563-8927)
- Adam Reich (ORCID: https://orcid.org/0000-0002-5573-1754)
- Chih‐Hung Lee (ORCID: https://orcid.org/0000-0001-9804-3874)
- Yoko Kataoka (ORCID: https://orcid.org/0000-0002-5121-0134)
- Andrew Blauvelt (ORCID: https://orcid.org/0000-0002-2633-985X)
- Natalie Rynkiewicz
- Stephan Weidinger (ORCID: https://orcid.org/0000-0003-3944-252X)
- Christine Weber (ORCID: https://orcid.org/0000-0003-0712-5255)
- Wanling Wong
Institutions
- Chang Gung University (TW)
- Sanofi (France) (FR)
- Osaka Prefectural Medical Center (JP)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Information Technology Association of America (US)
- Sanofi (Switzerland) (CH)
- Sanofi (United States) (US)
- University Hospital Schleswig-Holstein (DE)
- Probity Medical Research (CA)
- Sanofi (United Kingdom) (GB)
- Skin Health Institute (AU)
- Charité - Universitätsmedizin Berlin (DE)
- University of Lübeck (DE)
- University of Rzeszów (PL)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1016/j.jaci.2024.10.031
- Citations
- 37
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 12.08